NeurologyLive

01/03/2026

🧠 Understanding MS: Autoimmune, Neurodegenerative—or Both?

In a new NeuroVoices interview, MS expert David A. Hafler, MD, reflects on how our understanding of multiple sclerosis has evolved—and why treating the disease earlier may be key to preventing long-term damage.

From immune mechanisms and B-cell therapies to the possible role of EBV, here’s what’s shaping the future of MS care: https://hubs.li/Q03ZllSj0

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

01/03/2026

🧠 What Alzheimer trials could change care next?

In NeurologyLive®’s Year in Review 2025, we highlight 8 ongoing Alzheimer disease studies that may reshape how the disease is treated—from early prevention trials to new amyloid and tau-targeting therapies.

Learn what researchers are watching and why it matters for patients and families: https://hubs.li/Q03ZljR60

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

01/02/2026

🧠📊 In , “buzzwords” often signal larger shifts in research and clinical care. As 2025 unfolds, terms like artificial intelligence, gene therapy, personalized therapy, neuroplasticity, and genetics are increasingly shaping discussions across subspecialties.

This article explores how these concepts reflect evolving approaches to studying, diagnosing, and managing neurologic disease.

👉 Read more: https://hubs.li/Q03YYBzd0

01/01/2026

A new year brings new opportunities to advance neurology care and research. Thank you for being part of our community—here’s to another year of insight, innovation, and collaboration. Happy New Year 🧠✨

12/28/2025

🧠📊 This Year in Medicine |

As part of HCPLive's This Year in Medicine series, NeurologyLive® examined emerging evidence on the role of GLP-1 receptor agonists across several neurologic conditions, including disease and other dementias, sleep disorders, disease, , , and cardiovascular-brain health.

This feature reviewed where the science currently stands, highlights remaining evidence gaps, and discusses potential implications for future care.

🔗 Read more: https://hubs.li/Q03YYBcR0

12/27/2025

🧠✨ Clinical trials shaping neurology in 2025

From multiple sclerosis and migraine to epilepsy, Alzheimer disease, and Long COVID, NeurologyLive®’s Year in Review 2025 highlights notable trials that launched this year across neurology.

🧪 Areas of focus include:
• Precision & personalized medicine
• Expanded disease-modifying and symptomatic therapies
• Digital health, biomarkers & neuromodulation
• Rare and pediatric neurologic disorders

👉 Read more: https://hubs.li/Q03Y__N10

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

12/27/2025

🧠✨ A look back at the biggest MS conversations of 2025

From earlier detection of disease progression to debates around high-efficacy treatment, NeurologyLive®’s Year in Review brings together top expert interviews that shaped multiple sclerosis care this year.

Key themes include:
🔍 Improving diagnosis—especially in pediatric & atypical cases
⚡ Treating early to prevent long-term disability
🌍 Addressing global gaps in access to care
🧪 Exploring emerging therapies like BTK inhibitors & CAR T-cells

Read more: https://hubs.li/Q03Y_T5J0

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

12/27/2025

🧠✨ Hopeful early data in Dravet syndrome research

New findings presented at AES 2025 spotlight ETX101, a one-time gene regulation therapy aiming to address the root cause of Dravet syndrome by boosting SCN1A expression in key brain cells.

In an interview with Joseph Sullivan, MD, early POLARIS trial results showed:
⚡ Reduced seizure burden in some children
📈 Faster-than-expected developmental gains
🧒 A focus on treating children early—when impact may matter most

👉 Read more: https://hubs.li/Q03Y_D9-0

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

12/26/2025

In a new guest article at NeurologyLive®, Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG), professor of medicine at the University of Toronto, explored the evolving landscape of developmental and epileptic encephalopathies in adults.

To learn more, check out the article on our site here: https://hubs.li/Q03YYtf20

12/26/2025

🧠🎮 Ready to challenge your brain?
This week’s NeurologyLive® Brain Games focuses on neuromodulation for Parkinson disease—from DBS targets to adaptive systems. Try the 3-question quiz and share your results!

Test your knowledge here 👉 https://hubs.li/Q03YXCfw0

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

12/25/2025

🧠 Phase 2 MS Trial Update

📌 Continuem’s remyelinating candidate PIPE-307 did not meet its primary endpoint in the VISTA trial for relapsing-remitting multiple sclerosis, though the therapy was found to be safe and well tolerated.

The placebo-controlled study evaluated PIPE-307’s effect on remyelination using binocular low contrast letter acuity. Despite the setback, Continuem plans to further analyze exploratory endpoints and publish the data, reinforcing its commitment to developing novel therapies for inflammatory and fibrotic diseases.

👉 Read more on what these findings mean for remyelination research in MS: https://hubs.li/Q03YZNvP0

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

12/25/2025

🧠✨ In 2025, key trends like artificial intelligence, gene therapy, personalized treatment, neuroplasticity, and genetics are transforming how neurologic diseases are diagnosed and treated. These innovations are helping clinicians move beyond one-size-fits-all care toward smarter, more individualized approaches.

📖 Dive into the full story: What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 👉 https://hubs.li/Q03YZPMh0

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.